Seven Fleet Capital Management LP Makes New Investment in KalVista Pharmaceuticals, Inc. $KALV

Seven Fleet Capital Management LP acquired a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the fourth quarter, HoldingsChannel reports. The firm acquired 48,412 shares of the specialty pharmaceutical company’s stock, valued at approximately $782,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KALV. Tudor Investment Corp ET AL acquired a new position in KalVista Pharmaceuticals during the third quarter valued at approximately $24,360,000. Vestal Point Capital LP boosted its position in KalVista Pharmaceuticals by 152.0% during the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock worth $30,524,000 after purchasing an additional 1,140,000 shares during the period. Parkman Healthcare Partners LLC boosted its holdings in shares of KalVista Pharmaceuticals by 155.5% during the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after acquiring an additional 1,055,940 shares during the period. Ameriprise Financial Inc. boosted its position in shares of KalVista Pharmaceuticals by 2,258.6% in the second quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock valued at $10,685,000 after acquiring an additional 905,053 shares during the period. Finally, Elmind Capital LP acquired a new stake in KalVista Pharmaceuticals during the fourth quarter worth approximately $12,941,000.

KalVista Pharmaceuticals Stock Performance

Shares of KALV opened at $27.00 on Friday. KalVista Pharmaceuticals, Inc. has a 12-month low of $9.83 and a 12-month high of $27.00. The stock has a 50-day moving average price of $24.72 and a 200-day moving average price of $19.20. The company has a market cap of $1.44 billion, a PE ratio of -7.80 and a beta of -0.12. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The company had revenue of $40.86 million during the quarter, compared to analyst estimates of $39.03 million. As a group, equities analysts forecast that KalVista Pharmaceuticals, Inc. will post -1.19 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Benjamin L. Palleiko sold 10,926 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $26.78, for a total value of $292,598.28. Following the transaction, the chief executive officer owned 479,989 shares in the company, valued at approximately $12,854,105.42. This trade represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Nicole Sweeny sold 1,489 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $26.78, for a total value of $39,875.42. Following the completion of the sale, the insider directly owned 59,291 shares in the company, valued at $1,587,812.98. The trade was a 2.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 254,602 shares of company stock worth $4,656,670. 4.30% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on KALV. Citizens Jmp downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. JonesTrading downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. Stifel Nicolaus increased their price target on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. HC Wainwright lowered KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the company from $37.00 to $27.00 in a report on Friday, May 1st. Finally, Needham & Company LLC cut KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. Three analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $30.60.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.